The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Joaquim Bellmunt

Solid Tumor Oncology Section

Medical Oncology Service

University Hospital del Mar-IMIM

Barcelona

Spain

[email]@*.imim.es

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Solid Tumor Oncology Section, Medical Oncology Service, University Hospital del Mar-IMIM, Barcelona, Spain. 2007 - 2011
  • Department of Oncology, Lund University Hospital, Sweden. 2009
  • Medical Oncology Service, Hospital del Mar - IMAS, Experimental Cancer Therapeutics Unit (URTEC) IMIM-H del Mar, Barcelona, Spain. 2007 - 2009
  • Servicio de Oncología. Hospital General Universitari Vall d'Hebrón. Barcelona, Spain. 2007
  • Hospital del MAR-IMAS, Autónoma University of Barcelona, Barcelona, Spain. 2007
  • Hospital Del Mar, Solid Tumor Oncology (GU & GI) Medical Oncology Service, Barcelona, Spain. 2007

References

  1. Experience with sorafenib and adverse event management. Bellmunt, J., Eisen, T., Fishman, M., Quinn, D. Crit. Rev. Oncol. Hematol. (2011) [Pubmed]
  2. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). Bellmunt, J., Trigo, J.M., Calvo, E., Carles, J., Pérez-Gracia, J.L., Rubió, J., Virizuela, J.A., López, R., Lázaro, M., Albanell, J. Lancet Oncol. (2010) [Pubmed]
  3. A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01. Bellmunt, J., Maroto-Rey, P., Trigo, J.M., Carles, J., Guillem, V., López-Martín, J.A., Antón-Torres, A., Urruticoechea, L. Clin. Transl. Oncol (2010) [Pubmed]
  4. Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients. Bellmunt, J., Fishman, M., Eisen, T., Quinn, D. Expert. Rev. Anticancer. Ther (2010) [Pubmed]
  5. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. Bellmunt, J., Choueiri, T.K., Fougeray, R., Schutz, F.A., Salhi, Y., Winquist, E., Culine, S., von der Maase, H., Vaughn, D.J., Rosenberg, J.E. J. Clin. Oncol. (2010) [Pubmed]
  6. The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations. Bellmunt, J., Guix, M. BJU Int. (2009) [Pubmed]
  7. The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce. Bellmunt, J., Négrier, S., Escudier, B., Awada, A., Aapro, M. Crit. Rev. Oncol. Hematol. (2009) [Pubmed]
  8. Predictive modelling in hormone-refractory prostate cancer (HRPC). Bellmunt, J., Carles, J., Albanell, J. Clin. Transl. Oncol (2009) [Pubmed]
  9. Impact of PSA implementation and combined radiation and hormonal therapy (RT+HT) on outcome of prostate cancer patients. Bellmunt, J., Macià, F., Malmusi, D., Llorente, J.A., Carles, J., Lloreta, J., Foro, P., Gelabert, A., Albanell, J., Castells, X. Eur. J. Cancer (2009) [Pubmed]
  10. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. Bellmunt, J., Théodore, C., Demkov, T., Komyakov, B., Sengelov, L., Daugaard, G., Caty, A., Carles, J., Jagiello-Gruszfeld, A., Karyakin, O., Delgado, F.M., Hurteloup, P., Winquist, E., Morsli, N., Salhi, Y., Culine, S., von der Maase, H. J. Clin. Oncol. (2009) [Pubmed]
  11. Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer. Bellmunt, J., Calvo, E., Castellano, D., Climent, M.A., Esteban, E., García del Muro, X., González-Larriba, J.L., Maroto, P., Trigo, J.M. Cancer Chemother. Pharmacol. (2009) [Pubmed]
  12. Optimal management of metastatic renal cell carcinoma: an algorithm for treatment. Bellmunt, J., Flodgren, P., Roigas, J., Oudard, S. BJU Int. (2009) [Pubmed]
  13. Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents. Bellmunt, J., Albiol, S., Suárez, C., Albanell, J. Crit. Rev. Oncol. Hematol. (2009) [Pubmed]
  14. Future developments in renal cell carcinoma. Bellmunt, J. Ann. Oncol. (2009) [Pubmed]
  15. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Bellmunt, J., Szczylik, C., Feingold, J., Strahs, A., Berkenblit, A. Ann. Oncol. (2008) [Pubmed]
  16. Clinical activity of vinflunine in transitional cell carcinoma of the urothelium and other solid tumors. Bellmunt, J., Delgado, F.M., George, C. Semin. Oncol. (2008) [Pubmed]
  17. Open to debate. The motion: perioperative chemotherapy in muscle invasive bladder cancer improves survival. Bellmunt, J., Hautmann, R.E. Eur. Urol. (2008) [Pubmed]
  18. Sorafenib TARGET trial results in Spanish patients. Bellmunt, J., González-Larriba, J.L., Climent, M.A., López-Vivanco, G., Urruticoechea, L., Albanell, J. Clin. Transl. Oncol (2007) [Pubmed]
  19. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Bellmunt, J., Paz-Ares, L., Cuello, M., Cecere, F.L., Albiol, S., Guillem, V., Gallardo, E., Carles, J., Mendez, P., de la Cruz, J.J., Taron, M., Rosell, R., Baselga, J. Ann. Oncol. (2007) [Pubmed]
  20. Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents. Bellmunt, J., Montagut, C., Albiol, S., Carles, J., Maroto, P., Orsola, A. BJU Int. (2007) [Pubmed]
  21. Chemotherapy for metastatic or unresectable bladder cancer. Bellmunt, J., Albiol, S. Semin. Oncol. (2007) [Pubmed]
  22. Medical management of advanced prostate cancer: a multidisciplinary team approach. Bellmunt Molins, J., Gelabert i Mas, A. Expert. Rev. Anticancer. Ther (2007) [Pubmed]
  23. Intermittent chemotherapy in metastatic androgen-independent prostate cancer. Bellmunt, J., Albiol, S., Albanell, J. BJU Int. (2007) [Pubmed]
 
WikiGenes - Universities